期刊文献+

关注0.1%CsA阳离子乳剂在眼表免疫性疾病中的合理选择及应用 被引量:1

Focusing on the rational application of 0.1%CsA cationic emulsion in ocular surface inflammatory disorder
下载PDF
导出
摘要 眼表免疫性疾病(OSID)是由全身免疫性疾病引起,或是有局部免疫系统参与的慢性炎性眼部疾病,通过在眼及其附属器产生持续性炎症而引起泪液高渗环境和眼表上皮损伤,从而导致或加重干眼。常见的免疫炎性相关眼表疾病包括春季角结膜炎(VKC)、干燥综合征、移植物抗宿主病、干眼、免疫性角膜疾病等,严重影响患者的视觉功能和生活质量。目前,OSID主要采用人工泪液和糖皮质激素滴眼液进行治疗,但治疗效果欠佳且不良反应风险较大,因此OSID的有效治疗一直面临很大挑战。环孢素A(CsA)是一种临床常用的免疫抑制剂,具有很强的免疫调节作用,但由于其既有眼用剂型的通透性低,在临床上的应用受到一定限制。CsA眼用制剂的研发改变了OSID的治疗策略,近来研发的0.1%CsA阳离子乳剂显著提高了CsA局部应用的作用效果及安全性,值得临床医生关注。眼科医生应该充分认识各种OSID的免疫相关病理机制,充分了解0.1%CsA阳离子乳剂对OSID的疗效、适应证、眼表局部应用方法、不良反应等,进而在各种OSID的治疗中进行合理选择。 Ocular surface inflammatory disorder(OSID)is a chronic ocular disease caused by systemic disorders or involving the local immune system.OSID induces persistent inflammatory reaction in the ocular adnexal connective tissues which in turn give rise to tear hypertonicity and ocular surface epithelial damage,leading to dry eye formation or progression.Common immune-related ocular surface diseases include vernal keratoconjunctivitis,Sj gren syndrome,graft versus host disease,dry eye and immune-related corneal disease,all of which can significantly impact the visual function and quality of life of patients.Current treatments including the use of artificial tears and glucocorticoid eye drops are not always effective and have the risk of adverse events.Cyclosporine A(CsA)is a commonly utilized immunosuppressant that has a strong immunomodulatory effect,but its clinical application is somewhat limited due to the low permeability of its current ophthalmic dosage form.The development of CsA ophthalmic agents has changed the treatment strategy for OSID.The development of 0.1%CsA cationic emulsion has significantly improved the efficacy and safety of topical CsA treatment,which is worth the attention.In order to rationally apply 0.1%CsA cationic emulsion to OSID,ophthalmologists should fully understand the immune-related pathogenesis of each OSID and comprehend the curative effect,indication,application methods and adverse events of topical CsA treatment.
作者 陆以腾 周旭娇 洪佳旭 Lu Yiteng;Zhou Xujiao;Hong Jiaxu(Department of Ophthalmology,Shanghai Eye&ENT Hospital of Fudan University,Shanghai 200031,China)
出处 《中华实验眼科杂志》 CAS CSCD 北大核心 2023年第5期417-420,共4页 Chinese Journal Of Experimental Ophthalmology
基金 国家自然科学基金项目(81970766、82171102) 上海市科技创新行动计划医学创新研究专项项目(22Y21900900)。
关键词 环孢素A 眼表免疫性疾病 干眼 春季角结膜炎 疗效 不良反应 阳离子乳剂 Cyclosporine A Ocular surface inflammatory disorder Dry eye disease Vernal keratoconjunctivitis Curative effect Adverse event Cationic emulsion
  • 相关文献

参考文献2

二级参考文献22

  • 1Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease [ J ]. Dtsch Arztebl Int, 2015,112 ( 5 ) : 71 - 81. doi : 10. 3238/ arztebl. 2015. 0071.
  • 2The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop[J]. Ocul Surf,2007,5(2) :75-92.
  • 3Chia EM,Mitchell P,Rochtchina E,et al. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study[ J ]. Clin Experiment Ophthalmol, 2003,31 (3) : 229 - 232. doi: 10. 104 6/j. 1442-9071. 2003. 00634. x.
  • 4Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women[J]. Am J Ophthalmol, 2003,136 (2) : 318-326. doi:10. 1016/S 0002-9394(03)00218-6.
  • 5Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for SjOgren "s syndrome: a data- driven,expert consensus approach in the Sj,gren's International Collaborative Clinical Alliance cohort. Sjgren's International Collaborative Clinical Alliance (SICCA) Research Groups[J]. Arthritis Care Res (Hoboken), 2012,64(4) : 475-487.
  • 6Gumus K, Cavanaqh DH. The role of inflammation and anti inflammation therapies in keratoconjunctivitis sicca [ J ]. Clin Ophthalmol, 2009,3 ( 6 ) : 57 -67. doi : 10. 2147/OPTH. $3023.
  • 7Gao J, Schwalb TA, Addeo JV, et al. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical cyclosporin A therapy [ J ]. Cornea, 1998,17 ( 6 ) : 654 - 663. doi : 10. 1097/00003226-199811000-00014.
  • 8Solomon A, Dursun D, Liu Z, et al. Pro-and anti-inflammatory forms of interleukinin-1 in the tear fliod and conjunctiva of patients with dry-eye disease [ J ]. Invest Opthalmol Vis Sci ,2001,42 (10) : 2283-2292.
  • 9Kunert KS,Tisdale AS,Stem ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjuctival lymphocytes[ J ]. Arch Ophthalmo1,2000,118( 11 ) : 1489-1496.
  • 10Ferrand-Drake M,Zhu C,Gido G, et al. Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations,as well as transloeation of apoptosis-indueing factor, eytoehrome e and caspase-3 activationin neurons exposed to transient hypoglycemia[J]. J Neurochem, 2003,85(6) : 1431-1442.

共引文献21

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部